- Home
- AKBA vs LEO Comparison
AKBA vs LEO Comparison
Compare AKBA & LEO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AKBA
- LEO
- Stock Information
- Founded
- AKBA 2007
- LEO 1987
- Country
- AKBA United States
- LEO United States
- Employees
- AKBA N/A
- LEO N/A
- Industry
- AKBA Biotechnology: Pharmaceutical Preparations
- LEO Trusts Except Educational Religious and Charitable
- Sector
- AKBA Health Care
- LEO Finance
- Exchange
- AKBA Nasdaq
- LEO Nasdaq
- Market Cap
- AKBA 336.2M
- LEO 394.9M
- IPO Year
- AKBA 2014
- LEO N/A
- Fundamental
- Price
- AKBA $1.91
- LEO $6.02
- Analyst Decision
- AKBA Strong Buy
- LEO
- Analyst Count
- AKBA 1
- LEO 0
- Target Price
- AKBA $7.50
- LEO N/A
- AVG Volume (30 Days)
- AKBA 2.2M
- LEO 200.2K
- Earning Date
- AKBA 11-07-2024
- LEO 01-01-0001
- Dividend Yield
- AKBA N/A
- LEO 4.01%
- EPS Growth
- AKBA N/A
- LEO N/A
- EPS
- AKBA N/A
- LEO 0.04
- Revenue
- AKBA $169,879,000.00
- LEO N/A
- Revenue This Year
- AKBA N/A
- LEO N/A
- Revenue Next Year
- AKBA $30.85
- LEO N/A
- P/E Ratio
- AKBA N/A
- LEO $152.00
- Revenue Growth
- AKBA N/A
- LEO N/A
- 52 Week Low
- AKBA $0.80
- LEO $4.98
- 52 Week High
- AKBA $2.48
- LEO $6.50
- Technical
- Relative Strength Index (RSI)
- AKBA 49.15
- LEO 29.42
- Support Level
- AKBA $1.74
- LEO $5.98
- Resistance Level
- AKBA $1.90
- LEO $6.47
- Average True Range (ATR)
- AKBA 0.08
- LEO 0.07
- MACD
- AKBA -0.02
- LEO -0.04
- Stochastic Oscillator
- AKBA 34.38
- LEO 8.31
About AKBA Akebia Therapeutics Inc.
Akebia Therapeutics Inc is a fully integrated biopharmaceutical company. The Company's operating segment is the business of developing and commercializing novel therapeutics for people with kidney disease. The current portfolio of the company includes Auryxia (ferric citrate), a medicine approved and marketed in the United States for the control of serum phosphorus levels in adult patients with dialysis-dependent chronic kidney disease and the treatment of iron deficiency anemia, in adult patients with non-dialysis-dependent chronic kidney disease, Vafseo (vadadustat), an oral hypoxia-inducible factor prolyl hydroxylase, inhibitor, is approved in Japan for the treatment of anemia due to chronic kidney disease, in adult patients, HIF-PH inhibitors in preclinical development.
About LEO BNY Mellon Strategic Municipals Inc.
BNY Mellon Strategic Municipals, Inc. is a diversified closed-end management investment company. The fund's investment objective is to maximize current income exempt from federal income tax to the extent consistent with the preservation of capital. Its products are Equity and Fixed Income Mutual Funds, Retail Money Market Funds, Government/Treasury Money Market Funds, Institutional Money Market Funds, and others.